NRXP — NRX Pharmaceuticals, Inc.
$2.66-1.12%
Last close: · regular session
Last 60 sessions
NRXP closed at $2.66 (-1.12%) on Oct 29, 2026. Active shelf registration (S-3/A, Dec 2025); dilution risk: critical. Float: 34.0M shares. Latest SEC filing: 8-K on Oct 16, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NRXP in the TickerWise workspace.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 29
- Website: https://nrxpharma.com
Latest SEC filings for NRXP
Latest NRXP news
- NRXP Stock Builds Momentum As FDA Ketamine Catalyst Nears
- NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge?
- FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
- NRX Pharmaceuticals, Inc. Estimates
- NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression Read article
- NRx Pharmaceuticals to Participate in Upcoming Investor Conferences Read article
- NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock Read article
- NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.